DAWN
Day One Biopharmaceuticals Inc

1,916
Mkt Cap
$2.21B
Volume
6.91M
52W High
$21.44
52W Low
$5.64
PE Ratio
-20.57
DAWN Fundamentals
Price
$21.44
Prev Close
$21.39
Open
$21.36
50D MA
$13.48
Beta
1.05
Avg. Volume
2M
EPS (Annual)
-$1.04
P/B
5.00
Rev/Employee
$888,662.92
$523.56
Loading...
Loading...
News
all
press releases
Day One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 1-Year High - Should You Buy?
Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 12-Month High - What's Next...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care PR Newswire VANCOUVER, BC, March 19, 2026...
PR Newswire·3d ago
News Placeholder
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Rating of "Hold" from Brokerages
Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) have earned an average recommendation of "Hold" from the eleven analysts that are currently covering the company...
MarketBeat·4d ago
News Placeholder
Mak Capital One LLC Invests $10.21 Million in Day One Biopharmaceuticals, Inc. $DAWN
Mak Capital One LLC acquired a new stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange...
MarketBeat·5d ago
News Placeholder
Algert Global LLC Buys 411,000 Shares of Day One Biopharmaceuticals, Inc. $DAWN
Algert Global LLC grew its stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 45.4% in the third quarter, according to its most recent disclosure with the Securities and...
MarketBeat·5d ago
News Placeholder
Are DAWN, TALK, UNF Obtaining Fair Deals for their Shareholders?
Are DAWN, TALK, UNF Obtaining Fair Deals for their Shareholders? Are DAWN, TALK, UNF Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, March 12, 2026 Insiders may stand to receive...
PR Newswire·10d ago
News Placeholder
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--DAWN, SEM, FONAR, and JHG
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--DAWN, SEM, FONAR, and JHG SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--DAWN, SEM, FONAR, and JHG...
PR Newswire·11d ago
News Placeholder
Day One Biopharmaceuticals (NASDAQ:DAWN) Given "Neutral" Rating at JPMorgan Chase & Co.
JPMorgan Chase & Co. reissued a "neutral" rating and set a $21.50 price target (down from $27.00) on shares of Day One Biopharmaceuticals in a research report on Wednesday...
MarketBeat·11d ago
News Placeholder
Day One Biopharmaceuticals' (DAWN) "Neutral" Rating Reiterated at HC Wainwright
HC Wainwright reissued a "neutral" rating and set a $21.50 price target (down from $22.00) on shares of Day One Biopharmaceuticals in a research report on Tuesday...
MarketBeat·12d ago
News Placeholder
Are DAWN and TALK Obtaining Fair Deals for their Shareholders?
Are DAWN and TALK Obtaining Fair Deals for their Shareholders? Are DAWN and TALK Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, March 9, 2026 Insiders may stand to receive...
PR Newswire·13d ago
<
1
2
...
>

Latest DAWN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.